Therapeutic applications of viscous and injectable poly(ortho esters)

Advanced Drug Delivery Reviews

Volumn 53, Issue 1, 2001, Pages 45-73

  Einmahl, Suzanne ^a,b   Capancioni, Sergio ^a   Schwach Abdellaoui, Khadija ^a   Moeller, Michael ^a   Behar Cohen, Francine ^b   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSERM   (France)

Author keywords

Biodegradable polymers; Dentistry; Drug delivery; Ophthalmology; Poly(ortho esters); Veterinary medicine

Indexed keywords

DISEASES; ESTERS; HYDROPHOBICITY; POLYMERS; PROTEINS; SYNTHESIS (CHEMICAL); TISSUE; VISCOSITY;

INJECTABLE MATERIALS;

CONTROLLED DRUG DELIVERY;

BETAMETHASONE; DEXAMETHASONE; FLUOROURACIL; GENTAMICIN; GONADORELIN DERIVATIVE; HEMOSTATIC AGENT; HYDROCORTISONE; HYDROXYPROLINE; INDOMETACIN; INSULIN; IVERMECTIN; LEVONORGESTREL; LYSOZYME; MAFENIDE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOBRONITOL; MITOMYCIN; NALTREXONE; NORETHISTERONE; PHENYLBUTAZONE; POLY(ORTHO ESTER); PROSTAGLANDIN E2; PYRIMETHAMINE; SOMATOMEDIN BINDING PROTEIN 1; TETRACYCLINE DERIVATIVE; TIMOLOL MALEATE; TOBRAMYCIN SULFATE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

BIOCOMPATIBILITY; BIODEGRADATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EYE DISEASE; GLAUCOMA SURGERY; HUMAN; NONHUMAN; OSTEOARTHRITIS; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; TISSUE REGENERATION; VETERINARY MEDICINE; VITREORETINOPATHY;

ANIMALS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS; POLYMERS; VISCOSITY;

EID: 0035803705     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00220-4     Document Type: Review

References (158)

1. Poly(ortho esters)
2. Poly(ortho esters): Their development and some recent applications
3. Preparation of poly(ortho esters) by the reaction of diketene acetals and polyols
4. Development of poly(ortho esters): A historical overview
5. Poly(ortho esters)
6. Poly(ortho esters)
7. Studies on microencapsulation of 5-fluorouracil with poly(ortho ester) polymers
8. Development of chronomers TM for narcotic antagonists
9. Preparation and evaluation of a bioerodible naltrexone delivery system
10. Controlled release of naltrexone pamoate from linear poly(ortho esters)
11. Steroid delivery systems for contraception
12. Release of norethindrone from polyacetals and poly(ortho esters)
13. Release of norethindrone from poly(ortho esters)
14. In vitro and in vivo release of levonorgestrel from poly(ortho esters). I. Linear polymers
15. In vitro and in vivo release of levonorgestrel from poly(ortho esters). II. Crosslinked polymers
16. The effect of copolymerized 9,10-dihydroxystearic acid on erosion rates of poly (ortho esters) and its use in the delivery of levonorgestrel
17. Use of poly(ortho esters) for the controlled release of 5-fluorouracil and a LHRH analogue
18. Prosthetic nerve grafts: A resorbable tube as an alternative to autogenous nerve grafting
19. Bone induction by composite of bioerodible polyorthoester and demineralized bone matrix in rats
20. The effect of a composite of polyorthoester and demineralized bone on the healing of large segmental defects of the radius in rats
21. Assessment in rats of a new bioerodible bone-wax-like polymer
22. Effect of local hemostatics on platelet aggregation
23. Effect of local hemostatics on bone induction in rats: A comparative study of bone wax, fibrin-collagen paste, and bioerodible polyorthoester with and without gentamicin
24. Inhibition of heterotopic osteogenesis in rats by a new bioerodible system for local delivery of indomethacin
25. Local delivery of indomethacin by a polyorthoester inhibits reossification of experimental bone defects
26. In vitro characterization and in vivo efficacy of a prostaglandin E2/poly(ortho ester) implant for bone growth promotion
27. Mechanical properties of biodegradable polymers and composites proposed for internal fixation of bone
28. Biocompatibility and mechanical properties of a totally absorbable composite material for orthopaedic fixation devices
29. Preliminary biocompatibility screening of several biodegradable phosphate fiber reinforced polymers
30. Evaluation of absorbable poly(ortho esters) for use in surgical implants
31. Six bioabsorbable polymers: In vitro acute toxicity of accumulated degradation products
32. Biocompatibility of solid poly(ortho ester)
33. Guided tissue regeneration and local delivery of insulinlike growth factor I by bioerodible polyorthoester membranes in rat calvarial defects
34. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries
35. Biocompatibility and effect on osteogenesis of poly(ortho ester) compared to poly(DL-lactic acid)
36. Technical note: Biomechanical analysis of two absorbable fracture fixation pins after long-term canine implantation
37. Controlled release of 5-fluorouracil from linear poly(ortho esters)
38. Poly(ortho ester) matrices for controlled release of the antitumour agent 5-fluorouracil
39. Evaluation of a prototype therapeutic system for prolonged, continuous topical delivery of homosulfanilamide in the management of Pseudomonas burn wound sepsis
40. Drug delivery from catalysed erodible polymeric matrices of poly(ortho esters)
41. Acid catalyzed poly(ortho ester) matrices for intermediate term drug delivery
42. Release of insulin from pH-sensitive poly(ortho esters)
43. Erodible poly(ortho ester) drug delivery systems: In vitro erosion in canine and USP-simulated gastric juice
44. Controlled gastric emptying. II. In vitro erosion and gastric residence times of an erodible device in beagle dogs
45. In vivo and in vitro release of ivermectin from poly(ortho ester) matrices. I. Crosslinked matrix prepared from ketene acetal end-capped prepolymer
46. Poly(ortho esters) as bioerodible matrices for the controlled delivery of pyrimethamine in chemoprophylaxis of malaria
47. Controlled release of tobramycin sulfate from poly(ortho esters) implantable discs for the treatment of osteomyelitis
48. Controlled delivery of an antiemetic agent using an injectable semi-solid poly(ortho ester) for the treatment of gastrointestinal disorder in dogs
49. Synthesis and characterization of a new biodegradable semi-solid poly(ortho ester) for drug delivery systems
50. Synthesis and analysis of viscous poly(ortho ester) analogs for controlled drug release
51. IR spectroscopy
52. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks
53. Influence of irradiation sterilization on a semi-solid poly(ortho ester)
54. X-ray photoelectron spectroscopy analysis of the surface chemical structure of some biodegradable poly(ortho esters)
55. Probing the surface chemical structure of some novel poly(ortho esters) prepared with N-methyl and N-phenyl ethanolamine by time-of-flight secondary ion mass spectrometry (ToF-SIMS)
56. The use of SIMS. XPS and in situ AFM to probe the acid catalysed hydrolysis of poly(ortho esters)
57. Determination of liquid chromatographic peak purity by electrospray ionization mass spectrometry
58. Semi-solid hydrophobic bioerodible poly(ortho ester) for potential application in glaucoma filtering surgery
59. Controlled drug release from bioerodible hydrophobic ointments
60. Pulsatile and delayed release of lysozyme from ointment-like poly(ortho esters)
61. Purity and stability assessment of a semi-solid poly(ortho ester) used in drug delivery system
62. Influence of irradiation sterilization on polymers used as drug carriers - A review
63. Gamma sterilization of a semi-solid poly(ortho ester) designed for controlled drug delivery-validation and radiation effects
64. Measurement of bacterial growth rates on polymers
65. The use of acidic and basic excipients in the release of 5-fluorouracil and mitomycin C from a semi-solid bioerodible poly(ortho ester)
66. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester)
67. Improved biocompatibility of a viscous bioerodible poly(ortho ester) by controlling the environmental pH during degradation
68. A new poly(ortho ester)-based drug delivery system for the adjunct treatment of filtering surgery
69. A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: Subconjunctival tolerance and in vitro release
70. Recent developments in the synthesis and utilization of poly(ortho esters)
71. Development of a tetracycline delivery system for the periodontal disease
72. Development of a drug delivery system for the treatment of periodontal disease based on bioerodible poly(ortho esters)
73. Synthesis and erosion studies of self-catalyzed poly(ortho esters)
74. Synthesis and characterization of self-catalyzed poly(ortho ester)
75. Synthesis and characterization of self-catalyzed poly(ortho esters) based on decanediol and decanediol-lactate
76. Hydrolysis and erosion studies of autocatalyzed poly(ortho esters) containing lactoyl-lactyl acid dimers
77. Control of molecular weight for auto-catalyzed poly(ortho ester) obtained by polycondensation reaction
78. Stereospecific and anionic ring-opening polymerization
79. Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery
80. Optimization of a novel bioerodible device based on auto-catalyzed poly(ortho esters) for controlled delivery of tetracycline to periodontal pocket
81. In vitro drug release from self-catalyzed poly(ortho ester): Case study of 5-fluorouracil
82. Poly(ortho esters): Recent developments for biomedical applications
83. Mucosal drug delivery: Intravitreal
84. Use of insoluble biodegradable polymers in ophthalmic systems for the sustained release of drugs
85. Bioerodible polymers for ocular drug delivery
86. Biodegradable polymers for the controlled release of ocular drugs
87. Challenges of intraocular drug delivery
88. Treatment of intraocular diseases with poly(ortho ester)-based drug delivery systems
89. Biotolerance of a semisolid hydrophobic biodegradable poly(ortho ester) for controlled drug delivery
90. Biocompatibility of a new semi-solid bioerodible poly(ortho ester) intended for the ocular delivery of 5-fluorouracil
91. New generation of poly(ortho esters): Synthesis, characterization, kinetics, sterilization and biocompatibility
92. Subconjunctival biocompatibility of a viscous bioerodible poly(ortho ester)
93. Hematological values in experimental animals
94. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application
95. Suprachoroidal space as a new route of sustained drug delivery for choroidal neovascularization
96. Basic science and clinical aspects of wound healing in glaucoma filtering surgery
97. Five-year follow-up of the fluorouracil filtering surgery study
98. Trabeculectomy with intraoperative 5-fluorouracil vs. mitomycin C
99. Intraoperative 5-fluorouracil for filtration surgery in the rabbit
100. The effect of fluorouracil on the corneal endothelium
101. Proliferative vitreoretinopathy
102. The mechanism of action of drugs for the treatment of vitreoretinal scarring
103. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease
104. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy
105. A new model of proliferative vitreoretinopathy
106. Preventative ophthalmology. Age-related macular degeneration
107. Age-related macular degeneration: A review of experimental treatments
108. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization
109. Local delivery of antimicrobial agents for the treatment of periodontal diseases
110. Angiogenesis inhibition by minocycline
111. A review of longitudinal studies that compared periodontal therapies
112. Supportive care of the periodontal patient
113. Tetracyclines in the management of periodontal diseases: A review
114. Chemically-modified tetracycline normalizes collagen metabolism in diabetic rats. A dose-response study
115. Controlled drug release in periodontics: A review of new therapies
116. Zero-order delivery with periodontal placement of tetracycline-loaded ethylene vinyl acetate fibers
117. Periodontal pocket treatment in beagle dogs using subgingival doxycycline from a biodegradable system. I. Initial clinical responses
118. A novel bioerodible injectable system based on poly(ortho ester) for the adjunctive treatment of advanced periodontal disease
119. Veterinary applications
120. Controlled-release products for the control of the estrus cycle in cattle, sheep, goats, deer, pigs, and horses
121. Fertility regulation in cattle
122. Use of progestagen-impregnated sponges inserted intravaginally or subcutaneously for the control of the oestrus cycle in the sheep
123. Conceptual and commercially available intravaginal veterinary drug delivery systems
124. Semi-solid autocatalyzed poly(ortho ester) as a new veterinary drug delivery system for estrus synchronization in ewes
125. In vivo evaluation of sustained release microspheres of metoclopramide hydrochloride in beagle dogs
126. Bioavailability of controlled-release metoclopramide. 1st communication: Single dose study
127. Study of pharmacokinetics and pharmacodynamics of two preparations of metoclopramide
128. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer
129. A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period
130. Controlled delivery of metoclopramide using an injectable semi-solid poly(ortho ester) for veterinary application
131. Surgical alternatives in regenerative therapy of the periodontium
132. Guided tissue regeneration in periodontal therapy
133. Bone regeneration using the principle of guided tissue regeneration
134. The use of biodegradable polylactic acid barrier materials in the treatment of grade II periodontal furcation defects in humans. Part II. A multicenter investigative surgical study
135. In vitro and in vivo comparison of bulk and surface hydrolysis in absorbable polymer scaffolds for tissue engineering
136. Review of pathogenesis and treatment of degenerative joint disease
137. Effects of exercise and polysulfated glycosaminoglycan on repair of articular cartilage defects in the equine carpus
138. Intraarticular hyaluronan injections in the treatment of osteoarthritis: State-of-the-art review
139. Effects of intravenous administration of sodium hyaluronate on carpal joints in exercising horses after arthroscopic surgery and osteochondral fragmentation
140. Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants
141. Intra-articular use of corticosteroids in the horse
142. Stable formulations of recombinant human growth hormone and interferon-γ for microencapsulation in biodegradable microspheres
143. Influence of process parameters on the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres
144. Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatine analogue
145. Poly(ortho esters) for the pulsed and continuous delivery of peptides and proteins
146. Release of BSA from poly(ortho ester) extruded thin strands